The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
18-Aug-16
$3.2 billion
Target:
Valves & Controls Business of Pentair
Acquiror:
Emerson
Advised Emerson, a diversified global technology and industrial company, on the acquisition of the Valves & Controls business of Pentair
09-Aug-16
$NA
Target:
Bionomics Limited
Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.
08-Aug-16
$87 million
Target:
Aquasana, Inc.
Acquiror:
A. O. Smith Corporation
Advised A. O. Smith Corporation, a leading manufacturer of residential and commercial water heaters and boilers, on the acquisition of Aquasana, a premium water treatment company, from L Catterton
28-Jul-16
$80 million
Target:
BioD, LLC
Acquiror:
Derma Sciences, Inc.
Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.
08-Jul-16
$555 million
Target:
New Enterprise Stone & Lime Co., Inc.
Advised New Enterprise Stone & Lime Co., Inc. on $555 million of secured financings, including a new $450 million senior secured term loan and substantial amendments to its existing $105 million ABL revolver
28-Jun-16
$NA
Target:
US rights to an authorized generic version of Adderall XR
Acquiror:
Prasco Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
28-Jun-16
$652 million
Target:
US rights to 37 approved and 5 pipeline generic products
Acquiror:
Mayne Pharma Group Limited
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
27-Jun-16
$156 million
Target:
ReachLocal
Acquiror:
Gannett
Served as independent financial advisor to the Board of Directors of Gannett in connection with its acquisition of ReachLocal
21-Jun-16
$586 million
Target:
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Impax Laboratories, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
20-Jun-16
$NA
Target:
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Zydus Cadila
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
16-Jun-16
$40 million
Target:
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Sagent Pharmaceuticals, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
15-Jun-16
$414 million
Target:
Aegerion Pharmaceuticals
Acquiror:
QLT Inc.
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
11-Jun-16
$350 million
Target:
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Dr. Reddy’s Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
16-May-16
$874 million
Target:
Equinix Data Center Assets
Acquiror:
Digital Realty Trust
Advised Digital Realty Trust, the world's largest wholesale colocation services and data center solutions provider, on its acquisition of a portfolio of eight carrier-neutral European data centers from Equinix
04-May-16
$NA
Target:
Portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs
Acquiror:
Ligand Pharmaceuticals
Advised CorMatrix Cardiovascular, a leading medical device company with a differentiated extracellular matrix technology, on the sale of a portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs
04-May-16
$NA
Target:
Affinia Group
Acquiror:
MANN+HUMMEL GmbH
Advised MANN+HUMMEL GmbH, a leading global manufacturer of filtration solutions, on the acquisition of the global filtration operations (excluding the Affinia South America operations) of Affinia Group
25-Apr-16
$3.4 billion
Target:
Divestment assets of Ball and Rexam
Acquiror:
Ardagh Group SA
Advised Ball Corporation on the acquisition of Rexam plc and provided a fairness opinion to the Board of Directors of Ball Corporation on the sale of select metal beverage can assets in Europe, Brazil and the United States to satisfy certain regulatory requirements in connection with its proposed acquisition of Rexam
22-Apr-16
$NA
Target:
Elavon do Brasil
Acquiror:
Stone Pagamentos
Advised Minneapolis-based US Bancorp, the fifth largest commercial bank in the United States, and the parent company of Elavon, Inc., in the sale of its 50.1 percent majority stake in São Paulo-based, Elavon do Brasil to Stone Pagamentos, a local market, privately-held merchant acquirer.
19-Apr-16
$NA
Target:
Total Care Medicaid Plan
Acquiror:
Molina Healthcare, Inc.
Advised Molina Healthcare Inc., a provider of managed health care services under the Medicaid and Medicare programs, on the acquisition of Universal American’s Total Care Medicaid plan
14-Apr-16
$NA
Target:
Frieze Events Ltd. / Frieze Publishing Ltd.
Acquiror:
WME | IMG Global
Advised Frieze, the premier art events and media company, on its strategic investment and partnership with WME IMG Global
18-Mar-16
$NA
Target:
Sewells Group
Acquiror:
MSX International
Advised WorldMark on the sale of Sewells Group to MSX International, a global provider of outsourced business solutions. Sewells, headquartered in Shanghai, is a leading provider of automotive dealership development services across Asia Pacific, Africa and the Middle East
16-Mar-16
$942 million
Target:
Rofin-Sinar Technologies, Inc.
Acquiror:
Coherent, Inc.
Advised Rofin-Sinar Technologies, Inc., a leading manufacturer of industrial laser sources and laser-based solutions and components, on its sale to Coherent, Inc., a leading provider of lasers and laser-based technology for scientific, commercial and industrial customers
07-Mar-16
$NA
Target:
Boehringer Ingelheim
Acquiror:
AbbVie
Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.
03-Mar-16
$NA
Target:
Perseus Books LLC
Acquiror:
Ingram Content Group Inc.
Advised Perseus Books LLC, a leading independent publishing company, on the sale of its client services business to Ingram Content Group Inc.
01-Mar-16
$NA
Target:
Perseus Books LLC
Acquiror:
Hachette Book Group, Inc.
Advised Perseus Books LLC, a leading independent publishing company, on the sale of its publishing business to Hachette Book Group, Inc.